newsfilter
← Latest News
PR Newswire·

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference

CRDL
  • Cardiol Therapeutics Inc. (NASDAQ: CRDL; TSX: CRDL) will participate in a Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference in Boston, MA, on August 11, 2026, at 9:00 a.m. EDT.
  • The event will take place at the InterContinental Boston Hotel in the Griffin/Robinson room, with a live webcast available on the company's investor website.
  • The Company's lead candidate, CardiolRx ™, is a small-molecule drug that modulates inflammasome pathway activation to treat inflammation & fibrosis associated with pericarditis, myocarditis, & heart failure.
  • The MAVERIC Program is evaluating CardiolRx ™ for recurrent pericarditis, comprising the completed Phase II MAvERIC-Pilot study & the ongoing pivotal Phase III MAVERIC trial, with Orphan Drug Designation granted by the U.S. FDA.
  • The ARCHER Program studied CardiolRx ™ for acute myocarditis, a leading cause of sudden cardiac death in individuals under 35, following a completed Phase II safety, tolerability, & efficacy study.
  • Cardiol is developing CRD-38, a novel subcutaneous formulation intended to treat inflammatory heart disease, including heart failure, a condition with U.S. healthcare costs exceeding $30 billion annually.